Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 10:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 22,173 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: control 2 Clear all
Enrolling by invitation Phase 4 Interventional

Trial of Reducing Inpatient Antibiotic Durations in Children

NCT07322146
View directory record Official record
Conditions
Pneumonia, Skin and Soft Tissue (SST) Infection, Urinary Tract Infections (UTIs)
Interventions
Study Drug Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Days to 17 Years
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Aurora, Colorado • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

NCT04850846
View directory record Official record
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

Open-Label Study Of Exemestane With Or Without Celecoxib In Postmenopausal Women With ABC Having Progressed On Tamoxifen

NCT00038103
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Exemestane, Celecoxib + Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2010 · Synced Oct 26, 2026, 10:09 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Vasodilators and Anti-Oxidant Therapy in Early ATN

NCT00286403
View directory record Official record
Conditions
Acute Renal Failure
Interventions
Fenoldopam Mesylate and/or MESNA
Drug
Lead sponsor
Southeast Renal Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 28, 2016 · Synced Oct 26, 2026, 10:09 PM EDT
Recruiting Phase 2 Interventional

Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder

NCT07226661
View directory record Official record
Conditions
Major Depressive Disorder (MDD)
Interventions
SPN-821 2400 mg, Placebo
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Recruiting Not applicable Interventional

Effects of Acupuncture on Symptoms of Stable Angina

NCT06311461
View directory record Official record
Conditions
Angina, Stable
Interventions
Acupuncture, Attention control
Procedure · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
21 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Not applicable Interventional Results available

A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease

NCT03557086
View directory record Official record
Conditions
End Stage Liver Disease
Interventions
Advance Care Planning Video Decision Support Tool, Verbal Narrative
Behavioral · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2024 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Anti-Sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers

NCT06354270
View directory record Official record
Conditions
Dentin Sensitivity
Interventions
Stannous fluoride toothpaste, Regular fluoride toothpaste (Crest Cavity Protection)
Drug
Lead sponsor
HALEON
Industry
Eligibility
18 Years to 65 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Melbourne, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 26, 2026, 10:09 PM EDT
Not yet recruiting Early Phase 1 Interventional

Topical Methylene Blue-Photodynamic Therapy (MB-PDT) for Burn Wound Infection

NCT07494773
View directory record Official record
Conditions
Burns, Wound Infection
Interventions
Methylene Blue, Blue Light Illumination
Drug · Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of Changes in Bone Mineral Density as a Function of Consuming Two Different Forms of Calcium Carbonate

NCT01857154
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Micronized Calcium Carbonate, Non-Micronized Calcium Carbonate, Vitamin D3
Dietary Supplement
Lead sponsor
Integrative Health Technologies, Inc.
Network
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Not applicable Interventional

Telehealth Delivered Physical Rehabilitation for an Ankle Sprain

NCT04520854
View directory record Official record
Conditions
Ankle Sprains, Telerehabilitation, Analgesic, Opioid, Analgesics, Non-narcotic, Anti-Inflammatory Agents, Non-Steroidal, Implementation Science, Acute Pain, Quality of Life
Interventions
Telehealth Protocol, Usual Care
Other
Lead sponsor
Kyle Kosik
Other
Eligibility
15 Years to 35 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 26, 2026, 10:09 PM EDT
Recruiting Phase 2 Interventional

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

NCT05535166
View directory record Official record
Conditions
Medulloblastoma
Interventions
Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 59 Months
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2035
U.S. locations
10
States / cities
Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Not applicable Interventional

Qigong Exercise May Benefit Patients With Fibromyalgia

NCT01333566
View directory record Official record
Conditions
Fibromyalgia
Interventions
Intervention Group, Placebo Comparator: Control Group
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 4, 2016 · Synced Oct 26, 2026, 10:09 PM EDT
Active, not recruiting Not applicable Interventional

A Clinical Trial for Self-Injurious Behavior

NCT03995966
View directory record Official record
Conditions
Self-Injurious Behavior
Interventions
Noncontingent Reinforcement (NCR), Combination Treatment
Behavioral
Lead sponsor
Hugo W. Moser Research Institute at Kennedy Krieger, Inc.
Other
Eligibility
4 Years to 25 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Recombinant Human Lactoferrin to Treat Severe Sepsis

NCT00630656
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
27
States / cities
Loma Linda, California • Sacramento, California • Sylmar, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2011 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

A Phase II Trial to Examine the Effect of Subcutaneous Exenatide (Bydureon®) on Glucose Control in Patients With Type I Diabetes

NCT01928329
View directory record Official record
Conditions
Type I Diabetes
Interventions
Exenatide (Bydureon®), Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
8
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy

NCT04836559
View directory record Official record
Conditions
Focal Onset Seizures
Interventions
JNJ-40411813, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 69 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
7
States / cities
Tucson, Arizona • Orlando, Florida • Port Orange, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 2 Interventional

A Phase 2, Multi-center Study to Evaluate the Efficacy and Safety of ONO-2952 in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

NCT01844180
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS)
Interventions
ONO-2952, ONO-2952 Matching Placebo
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
48
States / cities
Anniston, Alabama • Goodyear, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2016 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

NCT03679780
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Risk Factor, Vasoconstriction
Interventions
BQ-788, BQ-123, L-Arginine, NG Nitro L Arginine Methyl Ester, Sodium Nitroprusside, Lactated Ringer's
Drug
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 35 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Phase 3 Interventional Results available

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone

NCT00528879
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo, Metformin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 77 Years
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Fresno, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2015 · Synced Oct 26, 2026, 10:09 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Prolonged Smoking Cessation Using Prescription Step Care

NCT00170079
View directory record Official record
Conditions
Tobacco Dependence
Interventions
Smoking Cessation Intervention
Behavioral
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
2
States / cities
Rochester, Minnesota • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 26, 2026, 10:09 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effect of Intraoral Transcutaneous Electrical Nerve Stimulation in Orthodontics Pain

NCT06573996
View directory record Official record
Conditions
Orthodontic Appliance, Pain, Transcutaneous Electric Nerve Stimulation, Orthodontic Appliance Complication
Interventions
Active TENS Device, Intervention 2: Placebo/Sham Device
Device
Lead sponsor
University of the Pacific
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 26, 2026, 10:09 PM EDT
Not listed Phase 4 Interventional

Ketorolac Sublingual vs. Fentanyl Intranasal in Pain Control for Bilateral Myringotomy and Tubes (BMT) Placement in Children

NCT02653742
View directory record Official record
Conditions
Pain, Postoperative, Otitis Media
Interventions
Ketorolac, Fentanyl
Drug
Lead sponsor
Anica Crnkovic
Other
Eligibility
8 Months to 7 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 26, 2026, 10:09 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

NCT05595642
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Astegolimab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
40 Years to 80 Years
Enrollment
1,290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
53
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 26, 2026, 10:09 PM EDT